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Summary A virtual model, using six predetermined criteria for fast tracking
tuberculosis specimens was devised to improve the cost effectiveness of the MB/
BacT system. All specimens received at a central laboratory were audited for the six
criteria over a 6-month period. By assuming that only those specimens fulfilling these
criteria were fast tracked the theoretical cost savings could be calculated. To
prevent possible delay in speciating mycobacteria, the number of criteria were
expanded to nine, and a further 6 month audit carried out
In the first 6-month period, 728 specimens were tested. Had the initial
hypothetical criteria excluded some of the specimens, only 351 specimens would
have been tested through the fast-track system at a saving of d942 ($1696), (52%) of
the total cost, but five culture results positive for environmental mycobacteria
would have been delayed. In a second 6-month survey the criteria were expanded.
Using these no positive culture would have been missed but the savings would only
have been 26% of the total cost.
Introducing exclusion criteria for rapid testing can improve the cost effectiveness
of rapid culture methods with no important loss of clinically necessary information.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Anyone working in medicine is aware of the need
for cost savings and of obtaining value for money.1
A trawl of literature seeking cost effective use of
resources in tuberculosis control revealed 114
references published in peer reviewed journals
since 1976. Relatively few papers were concerned
with cost effectiveness or cost savings of diagnostic
methods.2–8 In developed countries, a very high
proportion of specimens tested for tuberculosis are
likely to be negative.
Though providing more rapid identification of the
tuberculosis organism, the liquid MB/BacT culture
system is more expensive than conventional tech-
niques using solid Lowenstein–Jensen media. We
have therefore devised a virtual model based on
pre-determined criteria to examine the cost effec-
tiveness of excluding certain specimens from the
fast culture (MB/BacT system). We have, by this
method, established specific criteria for fast track-
ing specimens using MB/BacT, which we believe,
provides the most cost-effective way of using the
system.
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Methods
In the laboratory carrying out the audit all speci-
mens are routinely cultured on sold Lowenstein–
Jensen medium as well as (MB/BacT).
In the MB/BacT system culture takes place in a
process bottle containing modified Middlebrook
7H9-broth medium supplemented with growth
factors. Bottles are inoculated with either sterile
production of CO2 in monitored continuously by an
infrared detection system.
Production of CO2 changes the color of a gas
permeable sensor in the base of the bottle. The
lighter color results in an increase of reflectance
units, which are being monitored and recorded by
the instrument every 10min. Readings are analyzed
by computer driven algorithms and once a pre-set
threshold has been reached, an audible signal
alerts the operator that a bottle should be entered
and further examined.
Confirmation of the presence of acid-fast bacilli
(AFB) is made by Stain.
Detection of positive MB/BacT cultures has on
average been found to be more sensitive and twice as
rapid as by conventional cultures on solid media.9–11
We first audited all respiratory specimens pro-
spectively, which arrived at the laboratory for
testing for mycobacteria during a 6-month period.
We set up hypothetical criteria to see how many
positive results would have been delayed if only the
specimens following the criteria had been put
through the fast-track system.
The criteria were as follows:
(1) At least one of the following mentioned on the
laboratory form
A. A previous history or contact with TB.
B. TB queried on laboratory form.
C. Haemoptysis.
D. Weight loss.
E. Night sweats.
F. Living abroad or recent travel history.
(2) All the specimens from a children’s hospital.
(3) All AFB smear positive specimens.
We then added 3 more criteria for a second 6-
month period of audit, to see if this could improve
the completeness of information without reducing
cost-effectiveness. In this second audit the criteria
for selection was as above plus the following
information:
(1) Patients with HIV þ ve serology.
(2) Shadowing on chest-X-ray
(3) All bronchial washings from non-ITU patients.
The cost of the MB/BacT bottles is given as d2.50
($4.50). A conversion rate of $1.80 to d1 has been
used throughout. Only information available on the
microbiology request from was used . No further
clinical information was sought. Specimens from
extra-pulmonary sites were not included in the
audits as, by the laboratory’s experience, positive
findings were likely to be very rare.
Results
Laboratory test specimens for which smear and
culture for TB were requested came from eight
hospitals in the region, which were three teaching
hospitals, four District general hospitals, and a
children’s hospitals.
During the first 6 months of the study our
laboratory received 728 respiratory specimens
requesting testing for AFB of which 571 were sputa
and 157 bronchial washings.
Of the 571 sputum specimens information given
on 308 (54%) of these fulfilled the criteria.
Of the original 571 sputum specimens 27(4.4%)
had a positive culture result, 22 from specimens
which would have fulfilled the criteria for fast track
and five which did not.
These five specimens, all of which were smear
negative, grew environmental Mycobacteria not M.
tuberculosis, which were; M. avium intracellulare
(3) and M. terrae (2) from four different patients
(Table 1).
In addition to the 571 sputum specimens, 157
bronchial washing specimens were tested for
Mycobacteria of which 43 specimens (26%) fulfilled
the criteria.
Only five out of 147 (3%) bronchial washing
specimens were subsequently culture positive for
M. tuberculosis.
If these criteria had been used to exclude some
specimens, which would not therefore have been
passed through the fast-track system, the use of
263 bottles at a cost of d657.50 ($1184) would have
been avoided. Only 43 (28%) bronchial washing
specimens fulfilled the criteria. Excluding the rest
would have saved 114 bottles at a cost of d285
($513).
The total saving in the 6-month period would
therefore have been d942 ($11696) or 52.5% of the
actual cost of d1795 ($3231) for fast tracking all the
728 specimens.
As the initial set of criteria would have
excluded five culture positive specimens, and in
order to improve the pick up rate we added three
more criteria, stated on the laboratory form in a
second 6 month prospective audit period. (See
above).
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During this second period we audited all the
specimens from just one hospital: the one with the
largest caseload.
A total of 325 sputum specimens and 98 bronchial
washings were tested during the second 6 months
period of which 236 (73%) sputum specimens and 83
(85%) bronchial washings fulfilled the criteria for
fast tracking.
Following these new criteria would have resulted
in a total of 89 bottles saved for sputum and 15
bottles saved for bronchial washings specimens at a
total cost of d260 ($468). The actual cost of fast
tracking all 417 specimens was d1042.50 ($1182).
Thus using the expanded set of criteria could have
made a saving of 25% of the costs. No positive
specimens would have been delayed in the second
audit (Table 2).
Comparing the two audits, the savings were
lower but still considerable in the second audit.
Discussion
We have shown that using sets of criteria, based on
information provided on the laboratory form, to
decide whether to fast-track specimens for bacter-
iological culture, can provide considerable cost
savings. The first audit using a relatively restricted
set of criteria would have saved approximately 50%
of the costs of the MB/BacTsystem. Had these been
used the results for four patients with smear
negative culture positive isolates for environmental
mycobacteria (sometimes called mycobacteria
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Table 1 Mycobacterial species by smear and culture result for the two periods of audit.
Sputum Bronchial washing
Smearþ Smear Smearþ Smear
Isolate Cultureþ Cultureþ Cultureþ Cultureþ Total
First 6 month audit (728 specimens)
M.tuberculosis 8 1 5 14
M.avium 3 3 6
M.kansasii 4 4
M.chelonae 1 1
M.gordonae 2 2
M.terrae 2 2
M. malmoense 2 1 3
Total 17 10 5 32
Second 6 month audit (423 specimens)
M. tuberculosis 11 4 5 1 21
M. avium 5 8 1 1 15
M.kansasii 2 2 1 5
M. chelonae 1 1 1 3
M. gordonae 9 9
M. terrae 0
M. malmoense 1 2 1 2 6
Total 19 26 9 5 59
Table 2 Cost savings for the two audits.
Audit 1.
Total specimens sent to lab. 728 Cost of MB/BacT d1820 ($3276)
Specimens fulfilling criteria 351 d877.50 ($1580)
Specimens not fulfilling criteria 377 Potential saving d942.50 ($1697) (52% of total)
Audit 2.
Total specimens sent to lab. 417 Cost of MB/BacT d1042.50 ($1877)
Specimens fulfilling criteria 315 d787.50 ($1418)
Specimens not fulfilling criteria 98 Potential saving d245 ($441) (24% of total)
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other than tuberculosis, non-tuberculous mycobac-
teria, atypical or opportunist mycobacteria) would
have been delayed.12 The clinical importance of
this is uncertain but unlikely to be significant.
Thus we would recommend the more restricted
criteria saving about 50% of costs be used. The
capital cost of the system has not been entered into
the calculations, as this would be the same whether
some or all of the specimens were passed through.
Many laboratories are now considering the use of
polymerase chain reaction (PCR) techniques to
speed the speciation of mycobacteria.13
These are still being evaluated but unlike the
MB/BacT system, PCR has a lower sensitivity and
specificity for mycobacteria than solid and liquid
media methods. Its main value is in the detection of
environmental mycobacteria in the presence of a
positive smear.14
The expense probably precludes their use in
developing countries where the relatively modest
cost of the BacT system may be more easily
affordable. An analysis similar to our study of the
way cost effectiveness of the more expensive MB/
BacT system could be used also applies to a PCR-
based rapid species identification system.
With increased awareness of tuberculosis there is
likely to be increasing demand for bacteriological
tests for AFB. In this study only 4.4% of tests produced
a positive culture. Some ability to reduce costs by
excluding tests unlikely to be positive from the
expensive fast-track system would be an advantage.
We have shown that blanket use of more rapid
and more expensive techniques of species (and
sensitivity) identification can be avoided with no
loss of clinically useful information in a setting of a
public health system in a Western European City. It
is probable that other centres can do the same but
the exact criteria they should use for specimen
selection may have to be determined locally.
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